The aim of the project submitted for expert evaluation is the preclinical development and clinical evaluation of the innovative PI3 delta kinase inhibitor (Phosphatidylinositol 3-Phosphatidylinositide 3-kinase). The proposed inhibitor will be developed towards a preclinical indication in the treatment of immune-mediated diseases. PI3K kinase belongs to the family lipid kinases. Delta isoform is specific to immune cells (Ito K. et al. (2007). J Pharmacol Exp Ther). Blocking of the PI3K delta amplified signal is thought to have a significant immunosuppressive effect with relatively low toxicity. The applicant’s work led to the identification of compounds inhibiting PI3K delta, including one high-activity candidate (IC50 = 5 nM) and satisfactory pharmacological parameters. Studies of efficiency in the mouse model of systemic lupus erythematosus have shown that the selected molecule strongly inhibits the development of the disease. In animals treated with an PI3K delta inhibitor, a decrease in lupus nephropathy and a significant reduction in mortality was observed. Reference number of the aid programme: SA.41471(2015/X) Purpose of public aid: Article: 25 EC Regulation No 651/2014 of 17 June 2014 declaring certain types of aid compatible with the internal market in the application of Articles 107 and 108 of the Treaty (OJ L. I'm sorry. EU L 187/1 of 26.06.2014).